Logo-jcvtr

J Cardiovasc Thorac Res. 2019;11(2): 79-84. doi: 10.15171/jcvtr.2019.15
PMID: 31384400        PMCID: PMC6669424

Original Article

Evaluation of drugs used in chronic heart failure at tertiary care centre: a hospital based study

Rinku Ghimire 1 * ORCID, Sahadeb Prasad Dhungana 2

Cited by CrossRef: 3

1- Alsultan M, Alamer R, Alammar F, Alzlaiq W, Alahmari A, Almalki Z, Alqarni F, Alshayban D, Alotaibi F, Asiri I, Alsultan F, Kurdi S, Almalki B. Prevalence of polypharmacy in heart failure patients: A retrospective cross-sectional study in a tertiary hospital in Saudi Arabia. Saudi Pharmaceutical Journal. 2023;31(12):101875 [Crossref]
2- Lee T, Cau A, Cheng M, Levin A, Lee T, Vinh D, Lamontagne F, Singer J, Walley K, Murthy S, Patrick D, Rewa O, Winston B, Marshall J, Boyd J, Tran K, Kalil A, Mcculoh R, Fowler R, Luther J, Russell J. Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors. CJC Open. 2021;3(7):965 [Crossref]
3- Tsutsui Y, Matsushima S, Enzan N, Noda E, Shinohara K, Hashimoto T, Ide T, Kinugawa S, Tsutsui H. Nationwide Temporal Trends in Clinical Characteristics and Treatment of Dilated Cardiomyopathy From 2003 to 2013 in Japan　― A Report From Clinical Personal Records ―. Circ J. 2023;87(4):500 [Crossref]
4- Russell J, Marshall J, Slutsky A, Murthy S, Sweet D, Lee T, Singer J, Patrick D, Du B, Peng Z, Cheng M, Burns K, Harhay M. Study protocol for a multicentre, prospective cohort study of the association of angiotensin II type 1 receptor blockers on outcomes of coronavirus infection. BMJ Open. 2020;10(12):e040768 [Crossref]